This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human C1q R1 / CD93 Protein, His Tag (MALS verified)
catalog :
C11-H5228
quantity :
50 ug, 1 mg
price :
290 USD, 1800 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
C11-H5228
product name :
Human C1q R1 / CD93 Protein, His Tag (MALS verified)
quantity :
50 ug, 1 mg
price :
290 USD, 1800 USD
quantity & price :
$290/50ug,$1800/1mg (500ug × 2)
target :
C1q R1
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human C1q R1, His Tag (C11-H5228) is expressed from human 293 cells (HEK293). It contains AA Thr 22 - Lys 580 (Accession # AAH28075).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human C1q R1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
CD antigen CD93 is also known as Complement component C1q receptor (C1QR1). which belongs to the Group XIV C-Type lectin family, a group containing two other members, endosialin (CD248) and thrombomodulin. CD93 contains one C-type lectin domain and five EGF-like domains. CD93 is highly expressed in endothelial cells, platelets, cells of myeloid origin, such as monocytes and neutrophils. CD93 is receptor for C1q, mannose-binding lectin (MBL2) and pulmonary surfactant protein A (SPA). CD93 may mediate the enhancement of phagocytosis in monocytes and macrophages upon interaction with soluble defense collagens and may play a role in intercellular adhesion.
References :
(1) Ghebrehiwet B., et al., 1997, J. Immunol. 159:1429-1436.
(2) Nepomuceno R.R., et al., 1999, J. Immunol. 162:3583-3589.
(3) Kittlesen D.J., et al., 2000, J. Clin. Invest. 106:1239-1249.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments